To the Editor: In their study of the clinical utility of lipid measures for prediction of coronary heart disease (CHD), Dr Ingelsson and colleagues1 suggest that the measurement of apolipoprotein B (apo B) or apolipoprotein A-I (apo A-I) and its ratio should not be used in clinical practice.
This conclusion was supported by the finding that the Apo B:Apo A-I ratio did not provide additional information over the total cholesterol:high-density lipoprotein cholesterol (HDL-C) ratio for the prediction of CHD in a population-based prospective cohort study of 3322 men and women from Framingham, Massachusetts. We believe that this conclusion is not adequately supported by their data for a number of reasons.
Sierra-Johnson J, Romero-Corral A, Lopez-Jimenez F. Utility of Different Lipid Measures to Predict Coronary Heart Disease. JAMA. 2008;299(1):35-36. doi:10.1001/jama.2007.3